Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

BCL9L anticorps (N-Term)

BCL9L Reactivité: Humain WB Hôte: Lapin Polyclonal RB41624 unconjugated
N° du produit ABIN1881110
  • Antigène Voir toutes BCL9L Anticorps
    BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))
    Épitope
    • 12
    • 9
    • 7
    • 1
    • 1
    • 1
    • 1
    AA 147-176, N-Term
    Reactivité
    • 27
    • 4
    • 4
    Humain
    Hôte
    • 26
    • 1
    Lapin
    Clonalité
    • 26
    • 1
    Polyclonal
    Conjugué
    • 10
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp BCL9L est non-conjugé
    Application
    • 20
    • 17
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB)
    Purification
    This antibody is purified through a protein A column, followed by peptide affinity purification.
    Immunogène
    This BCL9L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 147-176 amino acids from the N-terminal region of human BCL9L.
    Clone
    RB41624
    Isotype
    Ig Fraction
    Top Product
    Discover our top product BCL9L Anticorps primaire
  • Indications d'application
    WB: 1:1000
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Date de péremption
    6 months
  • Miller, Rutherford, Johnson, Fiedler, Bienz: "Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor." dans: Journal of molecular biology, Vol. 401, Issue 5, pp. 969-84, (2010) (PubMed).

    Fritzmann, Morkel, Besser, Budczies, Kosel, Brembeck, Stein, Fichtner, Schlag, Birchmeier: "A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential." dans: Gastroenterology, Vol. 137, Issue 1, pp. 165-75, (2009) (PubMed).

    Sampietro, Dahlberg, Cho, Hinds, Kimelman, Xu: "Crystal structure of a beta-catenin/BCL9/Tcf4 complex." dans: Molecular cell, Vol. 24, Issue 2, pp. 293-300, (2006) (PubMed).

    Brembeck, Schwarz-Romond, Bakkers, Wilhelm, Hammerschmidt, Birchmeier: "Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions." dans: Genes & development, Vol. 18, Issue 18, pp. 2225-30, (2004) (PubMed).

  • Antigène
    BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))
    Autre désignation
    BCL9L (BCL9L Produits)
    Synonymes
    anticorps BCL9-2, anticorps DLNB11, anticorps B9L, anticorps BC003321, anticorps bcl9-2, anticorps BCL9L, anticorps B-cell CLL/lymphoma 9 like, anticorps B cell CLL/lymphoma 9-like, anticorps B-cell CLL/lymphoma 9-like, anticorps BCL9L, anticorps Bcl9l, anticorps bcl9l
    Sujet
    Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1 (By similarity).
    Poids moléculaire
    157129
    NCBI Accession
    NP_872363
    UniProt
    Q86UU0
    Pathways
    Stem Cell Maintenance
Vous êtes ici:
Support technique